Insider · CIK 0001221355

Kazam Joshua A

Reports to the SEC for 13 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001221355

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-18	ALLOAllogene Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+47.7K sh	—	—	398,463
2026-06-18	ALLOAllogene Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	Director	MExercise/Conversion	−47.7K sh	—	—	0
2026-06-18	ALLOAllogene Therapeutics, Inc. · Restricted Stock UnitA Award	Director	AAward	+95.4K sh	—	—	95,400
2025-12-18	ALLOAllogene Therapeutics, Inc. · Restricted Stock UnitM Exercise/Conversion	Director	MExercise/Conversion	−47.7K sh	—	—	47,700
2025-12-18	ALLOAllogene Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+47.7K sh	—	—	350,763
2025-06-20	Kronos Bio, Inc.U Disposition from Tender	Director	UDisposition from Tender	−94.5K sh	$0.57	−$53.9K	0
2025-06-20	Kronos Bio, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−34K sh	—	—	0
2025-06-20	Kronos Bio, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−34K sh	—	—	0
2025-06-20	Kronos Bio, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−34K sh	—	—	0
2025-06-20	Kronos Bio, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20.6K sh	—	—	0
2025-06-18	ALLOAllogene Therapeutics, Inc. · Restricted Stock UnitA Award	Director	AAward	+94.5K sh	—	—	94,500
2024-06-25	Kronos Bio, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+34K sh	—	—	34,000
2024-06-05	ALLOAllogene Therapeutics, Inc. · Stock Option (Right to buy)A Award	Director	AAward	+191K sh	—	—	191,082
2023-06-22	Kronos Bio, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+34K sh	—	—	34,000
2023-06-13	ALLOAllogene Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+116K sh	—	—	116,120
2022-06-22	Kronos Bio, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+34K sh	—	—	34,000
2022-06-15	ALLOAllogene Therapeutics, Inc.A Award	Director	AAward	+44.2K sh	—	—	303,063
2022-03-07	ALLOAllogene Therapeutics, Inc.G Gift	Director	GGift	−413K sh	—	—	258,885
2022-03-07	Kronos Bio, Inc.G Gift	Director	GGift	+211K sh	—	—	305,481
2022-03-07	Kronos Bio, Inc.G Gift	Director	GGift	−211K sh	—	—	94,481
2022-03-07	ALLOAllogene Therapeutics, Inc.J Other	Director	JOther	+413K sh	—	—	671,503
2022-01-12	ALLOAllogene Therapeutics, Inc.P Purchase	Director	PPurchase	+15K sh	$12.60	+$189K	258,885
2021-06-22	Kronos Bio, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+20.6K sh	—	—	20,600
2021-06-11	ALLOAllogene Therapeutics, Inc.G Gift	Director	GGift	−500K sh	—	—	243,885
2021-06-10	ALLOAllogene Therapeutics, Inc.A Award	Director	AAward	+16.5K sh	—	—	743,885
2021-06-04	LTCHLatch, Inc.M Exercise/Conversion	Former Director	MExercise/Conversion	+30K sh	—	—	30,000
2021-06-04	LTCHLatch, Inc. · Class B common stockM Exercise/Conversion	Former Director	MExercise/Conversion	−30K sh	—	—	0
2021-02-12	Tishman Speyer Innovation Corp. IIRedeemable warrantsP Purchase	Director	PPurchase	+5,000 sh	—	—	5,000
2021-02-12	Tishman Speyer Innovation Corp. IIP Purchase	Director	PPurchase	+25K sh	—	—	25,000
2020-10-21	ALLOAllogene Therapeutics, Inc.G Gift	Director	GGift	−306K sh	—	—	727,387
2020-10-14	Kronos Bio, Inc.Series Seed Preferred StockC Conversion	Director	CConversion	−22.3K sh	—	—	0
2020-10-14	Kronos Bio, Inc.C Conversion	Director	CConversion	+23.6K sh	—	—	25,666
2020-10-14	Kronos Bio, Inc.C Conversion	Director	CConversion	+68.8K sh	—	—	94,481
2020-10-14	Kronos Bio, Inc.Series A Preferred StockC Conversion	Director	CConversion	−65.2K sh	—	—	0
2020-06-05	ALLOAllogene Therapeutics, Inc.A Award	Director	AAward	+9,969 sh	—	—	1,033,305
2020-04-24	ALLOAllogene Therapeutics, Inc.J Other	Director	JOther	+8,039 sh	—	—	1,023,336
2020-03-04	ALLOAllogene Therapeutics, Inc.J Other	Director	JOther	+8,217 sh	—	—	1,015,297
2019-12-31	DraftKings Holdings Inc.Class B Common StockJ Other	Director	JOther	+20K sh	$0.00	+$2	20,000
2019-11-19	ALLOAllogene Therapeutics, Inc.J Other	Director	JOther	+8,217 sh	—	—	1,453,703
2019-11-11	ALLOAllogene Therapeutics, Inc.G Gift	Director	GGift	−447K sh	—	—	1,007,080
2019-10-25	ALLOAllogene Therapeutics, Inc.J Other	Director	JOther	+8,217 sh	—	—	1,445,486
2019-09-23	ALLOAllogene Therapeutics, Inc.J Other	Director	JOther	+8,217 sh	—	—	1,437,269
2019-09-05	ALLOAllogene Therapeutics, Inc.J Other	Director	JOther	+8,217 sh	—	—	1,429,052
2019-07-18	ALLOAllogene Therapeutics, Inc.J Other	Director	JOther	+8,217 sh	—	—	1,420,835
2019-07-10	ALLOAllogene Therapeutics, Inc.J Other	Director	JOther	+5,590 sh	—	—	1,412,618
2019-06-06	ALLOAllogene Therapeutics, Inc.A Award	Director	AAward	+16.4K sh	—	—	1,407,028
2019-03-05	THTarget Hospitality Corp.P Purchase	Director	PPurchase	+5,000 sh	$10.20	+$51K	10,000
2019-03-01	THTarget Hospitality Corp.P Purchase	Director	PPurchase	+5,000 sh	$10.13	+$50.7K	5,000
2019-01-22	THTarget Hospitality Corp. · Class B Ordinary SharesP Purchase	Director	PPurchase	+20K sh	$0.00	+$62	20,000
2018-10-15	ALLOAllogene Therapeutics, Inc.C Conversion	Director	CConversion	+18.7K sh	—	—	1,390,651

Recent filings

Accepted (ET)
Jun 234
Kazam Joshua A0001221355-26-000002
SEC(opens sec.gov)
Dec 224
Kazam Joshua A0001221355-25-000005
SEC(opens sec.gov)
Jun 234
Kazam Joshua A0001737287-25-000071
SEC(opens sec.gov)
Jun 204
Kazam Joshua A0001415889-25-017827
SEC(opens sec.gov)
Jun 264
Kazam Joshua A0001415889-24-018232
SEC(opens sec.gov)
Jun 74
Kazam Joshua A0001593968-24-000836
SEC(opens sec.gov)
Jun 264
Kazam Joshua A0001209191-23-039687
SEC(opens sec.gov)
Jun 154
Kazam Joshua A0001593968-23-001007
SEC(opens sec.gov)
Jun 294
Kazam Joshua A0001209191-22-039778
SEC(opens sec.gov)
Jun 174
Kazam Joshua A0001214659-22-008170
SEC(opens sec.gov)
Mar 94
Kazam Joshua A0001209191-22-017600
SEC(opens sec.gov)
Mar 94
Kazam Joshua A0001214659-22-003836
SEC(opens sec.gov)

Companies

Address

210 EAST GRAND AVENUE

SOUTH SAN FRANCISCO, CA, 94080